Tixagevimab and cilgavimab – September 2022

Tixagevimab and cilgavimab: Pack containing 1 vial of tixagevimab 150 mg in 1.5 mL and 1 vial of cilgavimab 150 mg in 1.5 mL; Evusheld® – September 2022 – December 2022 PBAC meetings

Brand names:
- Evusheld®
Pharmaceutical Company:
- AstraZeneca Pty Ltd
Condition/Indication: Pre-exposure prevention of COVID-19
Meeting Date: September 2022
Public Summary Document (PSD) September 2022 December 2022 PBAC Meetings - (PDF 1.9MB)
Public Summary Document (PSD) September 2022 December 2022 PBAC Meetings - (Word 2.7MB)

Related Public Summary Documents

Tixagevimab and cilgavimab – December 2022

Last updated

6 April 2023